Vivos Inc (RDGL)

[WALLnut]

Here's a small fraction of facts that Korenko has accomplished in his tenure as CEO.

Dr. Michael Korenko has achieved several significant milestones for Vivos Inc. and Radiogel since becoming CEO in 2017:

FDA Breakthrough Device Designation: In December 2023, Radiogel™ received the FDA’s Breakthrough Device Designation, which will expedite the review process for human clinical trials1.

OTCQB Certification: Under Dr. Korenko’s leadership, Vivos Inc. achieved OTCQB certification, highlighting the company’s commitment to transparency and regulatory compliance2.

Expansion of IsoPet® Clinics: Vivos Inc. expanded its IsoPet® division, which focuses on animal cancer treatment, to 8 regional clinics across the United States2.

Completion of QMS and Biocompatibility Testing: Dr. Korenko oversaw the completion of the Quality Management System (QMS) and the initiation of biocompatibility testing, crucial steps towards bringing Radiogel™ to the human market3.

Development of Precision Radionuclide Therapy™: Vivos Inc. developed a Yttrium-90 based injectable device for treating tumors in animals and humans, known as Precision Radionuclide Therapy™2.

These are just some of the undisputed facts that you fail to realize. But dont worry, im here to make sure you dont forget.